Phaseline

Targets › CAMK2D

CAMK2D (Calcium/calmodulin-dependent protein kinase type II subunit delta): drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 2; Cardiovascular; next expected readout Apr 2027.

Calcium/calmodulin-dependent protein kinase involved in the regulation of Ca(2+) homeostatis and excitation-contraction coupling (ECC) in heart by targeting ion channels, transporters and accessory proteins involved in Ca(2+) influx into the myocyte, Ca(2+) release from the sarcoplasmic reticulum (SR), SR Ca(2+) uptake and Na(+) and K(+) channel transport. Targets also transcription factors and signaling molecules…. (UniProt, Q13557)

Open in Phaseline: the race on CAMK2D, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Cardurion PharmaceuticalsCRD-4730
Calcium/calmodulin-dependent protein kinase II (CaMKII) inhibitor
CAMK2A, CAMK2B, CAMK2D, CAMK2GPhase 2Catecholaminergic Polymorphic Ventricular Tachycardia; Heart Failure With Reduced Ejection Fraction (HFrEF)Apr 2027

Conditions

Catecholaminergic Polymorphic Ventricular Tachycardia (1) Heart Failure With Reduced Ejection Fraction (HFrEF) (1)

Modalities

small molecule (1)

Companies

Cardurion Pharmaceuticals (1)

Related targets

CAMK2A (1) CAMK2B (1) CAMK2G (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.